Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBPNASDAQ:FBRXNASDAQ:SLGLNASDAQ:VINC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$8.31+0.4%$7.50$4.64▼$61.90$101.69M3.11347,221 shs68,090 shsFBRXForte Biosciences$12.44+0.5%$8.47$4.11▼$28.68$81.93M2.85159,193 shs16,980 shsSLGLSol-Gel Technologies$7.20+2.9%$7.06$3.34▼$16.50$19.89M1.132,827 shs3,034 shsVINCVincerx Pharma$0.05+4.9%$0.08$0.04▼$17.17$283K1.75431,967 shs18,744 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-9.38%+9.78%+44.52%-81.03%FBRXForte Biosciences0.00%-0.80%+63.47%+52.26%+58,030.84%SLGLSol-Gel Technologies0.00%+4.35%-7.69%+34.33%-17.21%VINCVincerx Pharma0.00%-8.16%+28.27%-91.67%-99.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals3.971 of 5 stars3.61.00.04.71.62.50.6FBRXForte Biosciences2.9869 of 5 stars3.53.00.00.03.51.70.6SLGLSol-Gel Technologies3.1196 of 5 stars3.55.00.00.00.01.70.6VINCVincerx Pharma3.2612 of 5 stars3.55.00.00.01.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$50.88512.21% UpsideFBRXForte Biosciences 3.00Buy$61.00390.35% UpsideSLGLSol-Gel Technologies 3.00Buy$40.00455.56% UpsideVINCVincerx Pharma 3.00Buy$40.0073,974.07% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, SLGL, VINC, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.004/1/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $61.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/ASLGLSol-Gel Technologies$11.54M1.74N/AN/A$10.36 per share0.69VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/14/2025 (Estimated)VINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%8/6/2025 (Estimated)Latest CRBP, SLGL, VINC, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million5/15/2025Q1 2025FBRXForte Biosciences-$0.89-$1.37-$0.48-$1.37N/AN/A5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A11.8211.82FBRXForte BiosciencesN/A5.225.22SLGLSol-Gel TechnologiesN/A5.125.12VINCVincerx PharmaN/A2.172.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%FBRXForte Biosciences77.63%SLGLSol-Gel Technologies26.18%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.60%FBRXForte Biosciences5.90%SLGLSol-Gel Technologies66.51%VINCVincerx Pharma15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableFBRXForte Biosciences56.58 million6.20 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableVINCVincerx Pharma605.23 million1.89 millionNot OptionableCRBP, SLGL, VINC, and FBRX HeadlinesRecent News About These CompaniesVincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution ProposalJune 18 at 4:18 PM | globenewswire.comVincerx Pharma announces plan to delist from NasdaqApril 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | finance.yahoo.comVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SECApril 17, 2025 | globenewswire.comVincerx's final merger attempt collapses, leaving ADC biotech to wind downApril 9, 2025 | fiercebiotech.comVincerx terminates letter of intent with Global Digital, initiates wind downApril 9, 2025 | markets.businessinsider.comFinancially struggling drugmaker's potential rescue falls apart. It now will wind downApril 9, 2025 | bizjournals.comVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesApril 8, 2025 | globenewswire.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisisMarch 18, 2025 | fiercebiotech.comVincerx Pharma Shares Soar on Proposed Merger with Global Digital HoldingsMarch 18, 2025 | marketwatch.comVincerx Pharma, Inc. Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | quiverquant.comVincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | globenewswire.comCash-strapped Vincerx left mulling future after Oqory reverse merger falls apartMarch 3, 2025 | fiercebiotech.comVincerx Pharma announces termination of reverse merger term sheetMarch 1, 2025 | markets.businessinsider.comVincerx Pharma Terminates Reverse Merger Deal With OqoryMarch 1, 2025 | marketwatch.comVincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic AlternativesFebruary 28, 2025 | quiverquant.comVincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic AlternativesFebruary 28, 2025 | globenewswire.comVINC stock touches 52-week low at $1.3 amid market challengesFebruary 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, SLGL, VINC, and FBRX Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$8.31 +0.03 (+0.36%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$8.56 +0.25 (+3.01%) As of 06/18/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Forte Biosciences NASDAQ:FBRX$12.44 +0.06 (+0.48%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$12.60 +0.17 (+1.33%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Sol-Gel Technologies NASDAQ:SLGL$7.20 +0.20 (+2.86%) Closing price 06/18/2025 03:58 PM EasternExtended Trading$7.35 +0.15 (+2.03%) As of 06/18/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.Vincerx Pharma NASDAQ:VINC$0.05 +0.00 (+4.85%) As of 06/18/2025 03:33 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
